Pathophysiology of Dupuytren's Contracture
| ISRCTN | ISRCTN88164211 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN88164211 |
| Protocol serial number | 6585 |
| Sponsor | Royal College of Surgeons of England (UK) |
| Funder | Healing Foundation |
- Submission date
- 11/08/2010
- Registration date
- 11/08/2010
- Last edited
- 18/04/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Liaquat Suleman-Verjee
Scientific
Scientific
Imperial College London
Kennedy Institute of Rheumatology Division
65 Aspenlea Road
London
W6 8LH
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicentre non-randomised interventional treatment trial |
| Secondary study design | Non randomised study |
| Study type | Participant information sheet |
| Scientific title | Pathophysiology of Dupuytren's Contracture |
| Study objectives | Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types. |
| Ethics approval(s) | MREC approved, ref: 06/Q0403/95 |
| Health condition(s) or problem(s) studied | Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery |
| Intervention | Elucidate the exact role of tenascin-C in Dupuytren's disease |
| Intervention type | Other |
| Primary outcome measure(s) |
Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 31/07/2011 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 90 |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 02/11/2006 |
| Date of final enrolment | 31/07/2011 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Imperial College London
London
W6 8LH
United Kingdom
W6 8LH
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
18/04/2017: No publications found, verifying study status with principal investigator.
